1. Antibodies
  2. Primary Antibodies
  3. Polyclonal Antibodies
  4. CHRNA9 Antibody

CHRNA9 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CHRNA9.

For research use only. We do not sell to patients.

Size Price Stock Quantity
10 μL In-stock
50 μL In-stock
100 μL In-stock
250 μL   Get quote  

* Please select Quantity before adding items.

Top Publications Citing Use of Products
  • WB: Western Blot;
  • IHC-P: Immunohistochemistry-Paraffin;
  • IHC-F: Immunohistochemistry-Frozen;
  • ICC/IF: Immunocytochemistry/Immunofluorescence;
  • IF-Tissue: Immunofluorescence-Tissue;
  • mIHC: Multiplex Immunohistochemical;
  • IP: Immunoprecipitation;
  • ChIP: Chromatin Immunoprecipitation;
  • FC: Flow Cytometry;
  • ELISA: Enzyme Linked Immunosorbent Assay
  • Product Detail

  • Verification Image

  • Background

  • Documentation

  • References

Description

CHRNA9 Antibody is a Rabbit-derived and non-conjugated IgG polyclonal antibody, targeting to CHRNA9.

Host

Rabbit

Clonality

Polyclonal

Molecular Weight
Predicted band size: 55 kDa;
Observed band size: 55 kDa
Note: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
Species Reactivity
Human, Rat
SwissProt ID
Gene ID
Immunogen

Synthetic peptide corresponding to human CHRNA9.The exact sequence is proprietary to MCE.

Application &
Dilution Ratio
Application Dilution Ratio
WB
WB: Western Blot
1:500-1:1000
IHC-P
IHC-P: Immunohistochemistry-Paraffin
1:50-1:100
Sensitivity Endogenous Conjugation Non-conjugated
Modification Unmodified Isotype IgG
Appearance

Liquid

Formulation

Supplied in pH 7.4 PBS, 0.05% NaN3, 40% Glycerol.

Storage & Stability

Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.

Shipping

Shipping with blue ice.

Verification Image
ALL WB IHC-P mIHC
  • Western blot analysis of extracts from Jurkat(lane 2(20μg) , HEK293T(lane 3(20μg) ,Rat skin tissue(lane 4(20μg)and Rat lung tissue( lane 5(20μg) using CHRNA9 Antibody (HY-P81023). Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody ( 1/1000) and Loading control antibody (Beta Actin, HY-P80993,1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Rabbit IgG-HRP Secondary Antibody (HY-P8001,1/10,000) was used for 1 hour at room temperature.

  • Immunohistochemical analysis of paraffin-embedded human Breast Cancer tissue using CHRNA9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81023, 1:300 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Breast Cancer tissue using CHRNA9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81023, 1:300 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Breast Cancer tissue using CHRNA9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81023, 1:300 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Ovarian Cancer‌ tissue using CHRNA9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81023, 1:300 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Ovarian Cancer‌ tissue using CHRNA9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81023, 1:300 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Immunohistochemical analysis of paraffin-embedded human Ovarian Cancer‌ tissue using CHRNA9 antibody was performed. The section was pretreated using high-temperature and high-pressure mediated EDTA antigen retrieval buffer (pH 9.0), for 5 minutes. The tissues were incubated with primary antibody (HY-P81023, 1:300 dilution) at room temperature for 60 minutes. Detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. The tissues were counterstained with hematoxylin and mounted with neutral balsam mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Breast Cancer tissue using CHRNA9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81023, 1:500 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Breast Cancer tissue using CHRNA9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81023, 1:500 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human Breast Cancer tissue using CHRNA9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81023, 1:500 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human ovarian carcinoma tissue using CHRNA9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81023, 1:500 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human ovarian carcinoma tissue using CHRNA9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81023, 1:500 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

  • Tyramide signaling amplification based immunofluorescence was performed on paraffin-embedded human ovarian carcinoma tissue using CHRNA9 antibody. Antigen retrieval was performed in EDTA buffer pH 9.0 (95 °C, 20 min) followed by cooling to RT. Then incubated with primary antibody (HY-P81023, 1:500 dilution) at room temperature for 60 minutes and HRP conjugated secondary antibody for 10 minutes. Fluorescence was then developed with Vari Fluor 532 TSA (200×)(HY-D1832). The tissues were counterstained with DAPI and mounted with Anti-fade mounting medium.

Background
Function:Component of neuronal acetylcholine receptors (nAChRs) that function as pentameric, ligand-gated cation channels with high calcium permeability among other activities. nAChRs are excitatory neurotrasnmitter receptors formed by a collection of nAChR subunits known to mediate synaptic transmission in the nervous system and the neuromuscular junction. Each nAchR subunit confers differential attributes to channel properties, including activation, deactivation and desensitization kinetics, pH sensitivity, cation permeability, and binding to allosteric modulators (PubMed:11752216, PubMed:18723036, PubMed:25282151). Forms either homopentamers or heteropentamers with CHRNA10. Expressed in the inner ear, in sympathetic neurons and in other non-neuronal cells, such as skin keratinocytes and lymphocytes (PubMed:11752216, PubMed:18723036). nAChR formed by CHRNA9:CHRNA10 mediate central nervous system control of auditory and vestibular sensory processing. The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, mediates synaptic transmission between efferent olivocochlear fibers and hair cells of the cochlea, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma (By similarity). May also regulate keratinocyte adhesion (PubMed:11021840, PubMed:11752216, PubMed:25282151)
Subcellular Localization:Synaptic cell membrane; Multi-pass membrane protein; Cell membrane; Multi-pass membrane protein
Expression:
Tissue_specificity:Expressed in cochlea, keratinocytes, pituitary gland, B-cells and T-cells
Subunit:Forms homo- or heteropentameric channels in conjunction with CHRNA10 (PubMed:11752216). The native outer hair cell receptor is composed of CHRNA9:CHRNA10 heterooligomers. Found in the stoichiometric form (CHRNA9)2:(CHRNA10)3 (By similarity)
RRID
Database
Documentation
References

CHRNA9 Antibody Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

 

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

     

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
CHRNA9 Antibody
Cat. No.:
HY-P81023
Quantity:
MCE Japan Authorized Agent: